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Introduction: The potential predictive role of BRCA1 and ERCC1 
expression levels in patients with metastatic non-small cell lung can-
cer (NSCLC) receiving second-line platinum-based chemotherapy 
was investigated.
Methods: Real-time quantitative polymerase chain reaction after 
reverse transcription was used to assess the expression levels of 
BRCA1 and ERCC1 in 100 microdissected primary tumors from 
platinum-naive NSCLC patients treated with platinum-based chemo-
therapy in the second-line setting.
Results: Low ERCC1 mRNA levels were significantly associated 
with higher response rate (p = 0.011), longer median progression-
free survival (PFS; p = 0.029), and median overall survival (moS; 
p = 0.001) after the initiation of the second-line treatment. Similarly, 
low BRCA1 expression level was significantly correlated with 
higher response rate (p = 0.022), longer PFS (p = 0.041), and moS 
(p = 0.005). In addition, patients with low ERCC1 and BRCA1 
mRNA experienced increased median PFS (p = 0.021) and moS 
(p < 0.001) in comparison with those who had both genes upregulated. 
A multivariate analysis revealed that low ERCC1 and low BRCA1 
expression levels were significantly associated with increased PFS 
(hazard ratio [HR]: 0.6; 95% confidence interval [CI]: 0.4–0.8; p = 
0.029 and HR: 0.7; 95% CI: 0.6–0.9; p = 0.043, respectively) and oS 
(HR: 0.5; 95% CI: 0.3–0.7; p = 0.003 and HR: 0.7; 95% CI: 0.6–0.9; 
p = 0.038, respectively).
Conclusions: These results suggest that the ERCC1 and BRCA1 
mRNA expression levels in the primary tumor at the time of diag-
nosis could be used for the prediction of platinum sensitivity in the 
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treatment of NSCLC in the second-line setting. Cross-validation 
studies are warranted.
Key Words: BRCA1, ERCC1, NSCLC, Cisplatin, Second-line 
chemotherapy.
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Non-small cell lung cancer (NSCLC) is the leading cause of cancer death among men and women worldwide, and 
almost 70% of them have locally advanced or metastatic dis-
ease at diagnosis.1 A combination of platinum compounds 
with third-generation agents (vinorelbine, gemcitabine, doc-
etaxel, and paclitaxel) has become the standard of palliative 
care for patients with stage IIIB/IV NSCLC and good per-
formance status (PS) and has significantly improved median 
survival and quality of life of these patients.2,3 Alternatively, 
chemotherapy regimens that do not contain platinum doublets 
have also been tested in several randomized phase III studies 
with substantial efficacy and a more favorable toxicity pro-
file in advanced/metastatic NSCLC patients.4–6 Despite these 
advances, most patients eventually relapse or become refrac-
tory to first-line chemotherapy generally within a median of 
3 to 6 months from the initiation of treatment. Docetaxel, 
pemetrexed, and erlotinib have been approved as the cur-
rent options of second-line treatment for advanced NSCLC 
patients with significant survival benefit and improvement of 
quality of life.7–10 However, the role of platinum efficacy in 
second-line treatment of NSCLC patients is not well defined 
because the majority of patients receive platinum compounds 
in the first-line setting. A few randomized phase II stud-
ies have evaluated the efficacy of platinum combinations in 
second-line therapy in either platinum-pretreated or platinum-
naive NSCLC patients.11–13 Nevertheless, the results from the 
second-line treatment combinations are disappointing with 
median survival of 8 months and 30% for 1-year survival.11
over the last decade, data from gene expression, muta-
tional, and proteomic profiling studies as well as from in 
vitro models led to the identification of molecular markers 
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that could influence the treatment decisions in the daily clini-
cal practice. A growing body of evidence is emerging for 
excision repair complementation group 1 (ERCC1) and breast 
cancer susceptibility gene 1 (BRCA1) and their role as poten-
tial predictors for platinum-based chemotherapy. ERCC1 is a 
rate-limiting enzyme in the nucleotide excision repair (NER) 
pathway, which recognizes and removes platinum adducts and 
repairs inter- and intrastrand cross-links.14 ERCC1 overexpres-
sion is associated with cellular resistance to platinum com-
pounds, whereas downregulation of ERCC1 sensitizes cells to 
cisplatin.15,16 ERCC1 has been evaluated as a prognostic17 and 
predictive18–20 biomarker for response and survival in NSCLC 
patients. Its predictive significance has also been shown in 
biopsies of ovarian21 and colorectal22 cancer patients.
Apart from its role in transcriptional regulation, cell 
cycle control, ubiquitination, apoptosis, and mitotic spindle 
assembly, BRCA1 has a prominent role in DNA repair and 
regulation of genome stability.23 BRCA1 is involved in plati-
num adducts removal as a component of transcription-coupled 
NER and homologous recombination repair pathways during 
the repair of double-strand breaks.24,25 Experimental26,27 and 
clinical28,29 studies have demonstrated that BRCA1 mRNA 
expression level is differentially associated with the response 
to chemotherapeutic drugs and ionizing irradiation. Low 
BRCA1 mRNA is correlated with cisplatin sensitivity and 
taxane resistance. The above-mentioned studies suggested 
that both BRCA1 and ERCC1 mRNA expression levels could 
predict resistance when platinum compounds were adminis-
tered in an adjuvant17,20,30 or first-line setting.5,6,19,31,32, However, 
it is still unknown whether the expression levels of BRCA1 
and ERCC1 in the primary tumor could predict NSCLC 
patient’s outcome when treated with second-line platinum-
based chemotherapy. In a previous retrospective study, we 
have observed that advanced NSCLC patients with low lev-
els of BRCA1 who had been treated with a docetaxel/gemcit-
abine regimen in the first-line setting, obtained the maximum 
benefit from cisplatin-based second-line chemotherapy.33 To 
confirm this observation, we investigated the relevance of this 
finding in an independent group of 100 additional patients by 
evaluating the role of BRCA1 and ERCC1 expression levels as 




Samples from primary tumors of NSCLC patients with 
histologically confirmed stage IV, who received a platinum-
based regimen as second-line treatment, were retrospectively 
collected and analyzed. These patients were selected from a 
cohort treated with nonplatinum-containing regimen as first-
line treatment, in the context of two randomized trials in which 
a nonplatinum doublet was compared with a platinum regi-
men (docetaxel + cisplatin versus docetaxel + gemcitabine5 
and vinorelbine + cisplatin versus docetaxel gemcitabine6) 
of the Hellenic oncology Research Group.5,6 After disease 
progression, the patients treated with nonplatinum doublet 
received cisplatin alone or a cisplatin combination regimen as 
second-line treatment in the context of a prospective random-
ized trial.11,12 The main eligibility criteria have been previously 
reported.5 The study has been approved by the institutional 
ethics and scientific committees and was conducted according 
to the Declaration of Helsinki. All patients signed a written 
consent form at the time of their initial evaluation both for 
the participation in the trial of frontline chemotherapy and for 
the use of their tissue for translational research. All laboratory 
analyses were performed blinded to the clinical data.
Specimens’ Characteristics and Assay Methods
Formalin-fixed paraffin embedded tumors were reviewed 
by two independent pathologists (E.L. and E.S.) to select the 
most appropriate area for microdissection. Serial sections 
of 5 m were prepared and stained with nuclear Fast Red 
(Sigma–Aldrich, St. Louis, Mo). An Eppendorf piezoelectric 
microdissector (Eppendorf, Hamburg, Germany) was used to 
procure only malignant cells. RNA extraction from microdis-
sected cells, reverse transcription, reverse-transcriptase poly-
merase chain reaction (RT-PCR) were performed as previously 
described.34 The primers and probe sets have been previously 
reported.35
Relative cDNA quantification was performed using the 
ABI Prism 7900HT Sequence Detection System (Applied 
Biosystems, Carlsbad, CA). Comparative C
t
 method was used for 
gene expression quantification using -actin and PGK1 as inter-
nal reference genes and commercial RNA (Stratagene, La Jolla, 
CA) as calibrators. Final expression values were determined as 
follows: 2–(Ct sample–Ct calibrator), where C
t
 values of the sample and 
FIGURE 1. Flow chart of the study.
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the calibrators are estimated by subtracting the C
t
 value of the 
target gene from the median values of the housekeeping genes. In 
all experiments, only triplicates with a standard deviation of the 
C
t
 value less than 0.25 were accepted. In addition, genomic DNA 
contamination was excluded by including nonreverse-transcribed 
RNA as a control for all 100 patients’ samples.
Study Design and Statistics
In this retrospective study, we aim to explore the pre-
dictive significance of BRCA1 and ERCC1 mRNA expression 
levels in the primary tumor of NSCLC platinum-naive patients 
treated with platinum-based second-line chemotherapy. All 
available biopsies of the primary tumor with more than 100 cells 
per section were analyzed. objective responses were recorded 
according to the RECIST criteria.36 All efficacy results were 
assessed on an intention-to-treat basis. Median progression-
free survival (PFS) and median overall survival (moS) were 
calculated from the start of second-line treatment to the docu-
mented disease progression or death, respectively. A quantita-
tive PCR analysis yielded values that were expressed as ratios 
between two absolute measurements (target gene:reference 
genes). Cutoff points were predefined and reported from previ-
ous investigations conducted in our laboratory.32
Correlations between treatment outcome parameters and 
mRNA expression levels were assessed using Fisher’s exact 
test. Kaplan–Meier curves were used to plot the correspond-
ing time-to-progression and survival curves. A univariate Cox 
regression analysis, with hazard ratios (HRs) and 95% confi-
dence intervals (CIs), was used to determine the association 
between each prognostic factor and clinical parameter. These 
factors were then included in a multivariate Cox proportional 
hazards regression model with a stepwise procedure (both for-
ward and backward) to evaluate the independent significance 
of different variables on survival and time to progression. 
Statistical significance was set at p = 0.05.
RESULTS
Patients’ Characteristics and mRNA Expression 
Levels
In total, 414 NSCLC patients were treated with doc-
etaxel plus gemcitabine in the context of two randomized 
TABLE 1. Patients’ Characteristics (N = 100)
Feature n Percentage
Median age (range) 63 (34–78)
  70 yr 74 74
 >70 yr 26 26
Gender
 Male 79 79
 Female 21 21
Tumor histology
 Squamous 23 23
 Nonsquamous 77 77
ECoG-PS
 0 26 26
 1 74 74
First-line regimens
 Docetaxel/gemcitabine 71 71
 Vinorelbine/gemcitabine 29 29
Response to first-line treatment
 CR + PR 38 38
 SD + PD 62 62
Second-line treatment
 Cisplatin + irinotecan 34 34
 Cisplatin 51 51
 Cisplatin + pemetrexed 15 15
ERCC1 mRNA expression level
 Squamous (median, 3.89) 23 23
  High 13 13
  Low 10 10
 Nonsquamous (median, 2.86) 77 77
  High 42 42
  Low 35 35
 All histologies
  High 55 55
  Low 45 45
 Treatment group
  Cisplatin + irinotecan Median, 2.93
   High 19 19
   Low 15 15
  Cisplatin Median, 2.88
   High 27 27
   Low 24 24
  Cisplatin + pemetrexed Median, 2.81
   High 9 9
   Low 6 6
BRCA1 mRNA expression levels
 Squamous (median, 8.10) 23 23
  High 14 14
  Low 9 19
 Nonsquamous (median, 3.62) 77 77
  High 40 40
  Low 37 37
 All histologies
  High 54 54
  Low 46 46
Feature n Percentage
 Treatment group
  Cisplatin + irinotecan Median, 4.85
   High 18 18
   Low 16 16
  Cisplatin Median, 4.69
   High 29 29
   Low 22 22
  Cisplatin + pemetrexed Median, 4.63
   High 9 9
   Low 6 6
ECoG, Eastern Cooperative oncology Group; PS, performance status; CR, complete 
response; PR, partial response; SD, stable disease; PD, progressive disease.
TABLE 1. Continued
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trials contacted by Hellenic oncology Research Group.5,6 
In total, 290 representative samples from the primary 
tumors of these patients were analyzed in the Laboratory 
of Tumor Cell Biology since 2006. Full clinical data, 
including patients’ management after progression to first-
line chemotherapy, were available for all patients. From 
the initial 290 patients, 131 were treated with a nonplati-
num-containing doublet in the context of two randomized 
clinical trials.5,6 one hundred of these 131 platinum-na-
ive patients had received cisplatin-based chemotherapy 
as second-line treatment (Figure 1).11,12 Patients’ charac-
teristics were typical for NSCLC and are summarized in 
Table 1. In an intention-to-treat analysis, partial response 
was observed in 14 (14%) patients (overall response rate 
[oRR] 14%; 95% CI: 8.2–23.6). After a median follow-up 
period of 9.9 months (range, 1.2–62.6 months), the median 
PFS was 3.3 months (95% CI: 1.9–4.6), and the moS was 
8.9 months (95% CI: 7.4–12.7). These results are compa-
rable with those reported for the whole population of the 
two studies.11,12
The cutoff points for the expression values of BRCA1 
and ERCC1 were previously predefined in our laboratory and 
were different for squamous and nonsquamous tumor, because 
the mRNA expression levels for BRCA1 and ERCC1 recorded 
in squamous cell carcinomas were significantly higher than 
those of adenocarcinomas (p = 0.001 for BRCA1 and p = 
0.03 for ERCC1, respectively), as previously reported.32,37 
Furthermore, a significant correlation between BRCA1 and 
ERCC1 mRNA expression levels (Spearman’s test 0.39; p = 
0.002) was observed. Using these predefined cutoff values, 
low (below the cutoff) tumoral BRCA1 expression level was 
observed in 46 patients (46%), whereas low expression level 
of ERCC1 was observed in 45 patients (45%) (Table 1). The 
ERCC1 and BRCA1 mRNA expression levels were similar 
across the three treatment groups with no statistical difference 
between them as shown in Table 1.
Genes’ Expression Levels and Response to 
Second-Line Cisplatin-Based Treatment
The correlations between response to treatment, PFS 
and moS, and BRCA1 and ERCC1 mRNA expression levels 
are summarized in Table 2. Patients with high BRCA1 mRNA 
expression level had significantly lower oRR (6% versus 
26%; p = 0.034) and decreased PFS (2.2 versus 4.0 months; 
p = 0.041; Figure 2A) and moS (6.7 versus 14.7 months; 
p = 0.005; Figure 3A) to second-line cisplatin-based chemother-
apy in comparison with those with low BRCA1 mRNA levels. 
Similarly, patients with high ERCC1 mRNA expression level, 
when they were treated with cisplatin-based chemotherapy in 
the second-line setting, experienced a lower oRR (7% versus 
29%, p = 0.013) and a shorter PFS (2.0 versus 4.2 months; p = 
0.003; Figure 2B) and moS (5.8 versus 15.8 months; p = 0.001; 
Figure 3B), as compared with patients whose tumors had low 
ERCC1 mRNA expression level. Moreover, second-line treat-
ment with cisplatin-based chemotherapy is significantly less 
efficacious in patients with overexpression of both BRCA1 and 
ERCC1 in their primary tumors in terms of oRR (4% versus 
30%; p = 0.006), PFS (2.0 versus 4.1 months; p = 0.002; Figure 
2C), and moS (5.4 versus 16 months; p = 0.001; Figure 3C) 
than in those patients with low mRNA expression level in their 
primary tumors. Finally, patients with low mRNA expression 
level of both BRCA1 and ERCC1 genes presented significantly 
higher oRR (30% versus 8%; p = 0.035), increased moS (16 
versus 8.8 months; p = 0.008; Figure 3C), and a statistical trend 
toward a longer PFS (4.1 versus 3.4 months; p = 0.054; Figure 
2C), as compared with patients with high mRNA expression 
level of either BRCA1 or ERCC1 genes.
Univariate and Multivariate Analyses
A univariate analysis demonstrated that high BRCA1 
(HR: 1.61, 95% CI: 1.20–2.83; p = 0.002) and ERCC1 (HR: 
1.82, 95% CI: 1.37–3.13; p = 0.001) mRNA expression 
level, Eastern Cooperative oncology Group–PS of 1 (HR: 
1.56, 95% CI: 1.29–2.58; p = 0.026), and no response to 










 (95% CI) pa CR + PR SD + PD pb
BRCA1 high 54 (54) 2.2 (1.7–2.8) 0.041 6.7 (3.1–7.8) 0.005 6 94 0.034
BRCA1 low 46 (46) 4.0 (2.7–5.8) 14.7 (10.9–23.2) 26 74
ERCC1 high 55 (55) 2.0 (1.7–2.3) 0.003 5.8 (5.1–6.5) 0.001 7 93 0.013
ERCC1 low 45 (45) 4.2 (3.0–5.4) 15.8 (9.9–21.7) 29 71
Both low 43 (43) 4.1 (2.2–6.2) 0.002c 16.0 (11.4–26.3) <0.001c 30 70 0.006c
Both high 45 (45) 2.0 (1.7–2.3) 0.054d 5.4 (2.9–7.8) 0.008d 4 96 0.035d
one high other low 12 (12) 3.4 (2.3–4.3) 8.8 (7.7–11.8) 8 92 0.048e
a Log-rank p value.
b 2 p value.
c Both low versus both high.
d Both low versus one high other low.
e Both high versus one high other low.
PFS, progression-free survival; oS, overall survival; RR, response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CI, confidence 
interval.
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first-line treatment (HR: 1.31, 95% CI: 1.26–1.98; p = 0.036) 
were significantly associated with decreased PFS, whereas 
age more than 70 years (p = 0.37), gender (p = 0.46), and 
histology (p = 0.32) were not significantly associated with 
the PFS (Table 3). Similarly, high BRCA1 (HR: 2.15, 95% 
CI: 1.21–3.80; p = 0.008) and ERCC1 (HR: 3.46, 95% CI: 
1.89–6.32; p < 0.001) mRNA expression level were associ-
ated with decreased moS. In addition, PS of 1 (HR: 1.52, 
95% CI: 1.02–2.38; p = 0.044) and no response to prior 
first-line chemotherapy (HR: 1.38, 95% CI: 1.14–2.62; p = 
0.041) were significantly correlated with decreased oS, 
whereas age (p = 0.39), gender (p = 0.52), and histology 
(p = 0.54) presented no significant impact on moS (Table 
3). A Cox proportional hazard analysis revealed that mRNA 
expression levels of BRCA1 (HR: 1.93, 95% CI: 1.46–1.87; 
p = 0.013) and ERCC1 (HR: 2.32, 95% CI: 1.36–3.96; p = 
0.002) emerged as the only independent factors associated 
with decreased PFS (Table 4). Similarly, BRCA1 (HR: 1.87, 
95% CI: 1.13–2.58; p = 0.016) and ERCC1 (HR: 1.91, 95% 
CI: 1.25–2.92; p = 0.003) mRNA expression levels were 
revealed as the only independent factors correlated with 
decreased moS (Table 4).
DISCUSSION
In the past decade, an overwhelming amount of data has 
been generated concerning the role of tumor molecular profiling 
to the chemotherapeutic drug activity. BRCA1 and ERCC1, two 
major components of NER and base excision repair pathways, 
respectively, have been proposed as predictive biomarkers of 
FIGURE 2. Progression-free survival (PFS) according to BRCA1 (A), ERCC1 (B), and BRCA1–ERCC1 combined (Cc mRNA 
expression levels. Lower levels of BRCA1 (A), ERCC1 (B), and both genes (C) were associated with significantly decreased PFS 
(for more details see Table 2).
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the treatment of NSCLC patients with platinum-based che-
motherapy in the adjuvant or first-line setting.18–20,30,33,38 In 
this study, the role of BRCA1 and ERCC1 mRNA expression 
levels on the outcome of NSCLC patients received second-
line platinum-based therapy was investigated. on the basis 
of our data, patients with low BRCA1 and/or ERCC1 mRNA 
expression levels attained a significantly higher RR and 
longer PFS and oS compared with those with high expres-
sion level of either gene. Moreover, the multivariate analy-
sis revealed that BRCA1 and ERCC1 expression levels were 
independent factors for PFS and oS. These results confirm 
our earlier findings for the predictive role of BRCA1 in a 
smaller cohort of 31 NSCLC patients treated with cispla-
tin-based combinations in the second-line setting.33 Taking 
together the results of the two studies support the previous 
findings for the differential predictive role of BRCA1 expres-
sion level concerning the response to cisplatin and antimicro-
tubule agents,27 and this hypothesis is currently being tested 
in a prospective randomized trial (BREC http:// clinicaltrials.
gov/ct2/show/NCT00617656?term=BREC&rank=1). In 
support of the clinical finding, in vitro studies using breast 
cancer cell lines have shown that decreased tumoral BRCA1 
mRNA levels increase the sensitivity to cisplatin and resis-
tance to antimicrotubule drugs; accordingly, low BRCA1 
expression level was associated with cisplatin efficacy in a 
variety of solid tumors.28,30,39 overexpression of ERCC1 and 
BRCA1 seems to be oncogene driven,40 and there is no clear 
explanation why these two as well as RRM1 are found upreg-
ulated especially in squamous cell lung cancer. In this study, 
the observed positive correlation (p = 0.002) between the 
FIGURE 3. Median overall survival (OS) according to BRCA1 (A), ERCC1 (B), and BRCA1–ERCC1 combined expression (C) 
mRNA expression levels. Lower levels of BRCA1 (A), ERCC1 (B), and both genes (C) were associated with significantly decreased 
progression-free survival (for more details see Table 2).
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TABLE 3. Univariate Analysis for PFS and OS
Hazard 
Ratio 95% CI p
PFS
 BRCA1 expression level  
(high vs. low)
1.61 1.20–2.83 0.002
 ERCC1 expression level  
(high vs. low)
1.82 1.37–3.13 0.001
 Response to first-line treatment 
(SD + PD vs. CR + PR)
1.31 1.26–1.98 0.036
 PS (1 vs. 0) 1.56 1.29–2.58 0.026
 Age (>70 yr vs. 70 yr) 1.24 0.79–1.78 0.37
 Gender (male vs. female) 1.12 0.86–1.95 0.46




 BRCA1 expression level  
(high vs. low)
2.15 1.21–3.80 0.008
 ERCC1 expression level  
(high vs. low)
3.46 1.89–6.32 <0.001
 Response to first-line treatment 
(SD + PD vs. CR + PR)
1.38 1.14–2.62 0.041
 PS (1 vs. 0) 1.52 1.02–2.83 0.044
 Age (>70 yr vs. 70 yr) 1.19 0.81–1.93 0.39
 Gender (male vs. female) 1.10 0.82–1.53 0.52
 Histology  
(squamous vs. nonsquamous)
1.13 0.83–1.24 0.54
PFS, progression-free survival; oS, overall survival; CR, complete response; PR, 
partial response; SD, stable disease; PD, progressive disease; CI, confidence interval; 
PS, performance status.
TABLE 4. Multivariate Analysis for Time to Tumor 
Progression and Overall Survival
Hazard 
Ratio 95% CI p
PFS
 Response to first-line treatment 
(SD + PD vs. CR + PR)
1.21 0.54–1.76 0.84
 BRCA1 expression level  
(high vs. low)
1.93 1.46–2.87 0.013
 ERCC1 expression level  
(high vs. low)
2.32 1.36–3.96 0.002
 PS (1 vs. 0) 1.19 0.62–1.76 0.67
oS
 Response to first-line treatment 
(SD + PD vs. CR + PR)
1.15 0.65–2.21 0.41
 BRCA1 expression level  
(high vs. low)
1.87 1.13–2.58 0.016
 ERCC1 expression level  
(high vs. low)
1.91 1.25–2.92 0.003
 PS (1 vs. 0) 1.21 0.72–1.96 0.44
PFS, progression-free survival; oS, overall survival; CR, complete response; PR, 
partial response; SD, stable disease; PD, progressive disease; PS, performance status; 
CI, confidence interval.
expression levels of BRCA1 and ERCC1 and the clinical out-
come after second-line platinum based-chemotherapy is in 
agreement with in vitro and in vivo studies.40 Furthermore, in 
the same line with previous reports was the find-
ing that the expression level of both genes is signifi-
cantly higher in squamous cell carcinoma (BRCA1, 
p = 0.001; ERCC1, p = 0.03) compared with adenocarci-
noma and other histological types.18,19,40 In addition, patients 
with low expression level of both BRCA1 and ERCC1 genes 
obtained the maximum benefit from cisplatin, with a signifi-
cantly higher RR, PFS, and oS.
Despite clinically meaningful activity of pemetrexed and 
docetaxel in NSCLC patients,7,8 the results from several phase 
III trials show that second-line treatment efficacy has reached 
a plateau, necessitating new directions for NSCLC treatment 
decisions. The option of using potential molecular predictors 
of response and survival in the basis of a customized treatment 
seems now to be reasonable. The data presented here imply 
that other known predictive biomarkers could be tested in 
NSCLC patients receiving second-line therapy. For example, 
high thymidylate synthetase levels, which is the main target 
of pemetrexed,41 were associated with reduced sensitivity of 
pemetrexed in cell lines.42,43 on the basis of the results of this 
study, an analysis for the predictive significance of thymidy-
late synthetase expression level to pemetrexed efficacy in the 
second-line treatment may be a reasonable approach for a sub-
sequent study.2,44
In this study, it is noteworthy that these results 
were obtained with the analysis of the initial biopsy of the 
primary tumor at the time of diagnosis. Despite the fact 
that differences in KRAS and/or endothelial growth fac-
tor receptor mutation status between primary tumor and 
metastasis have been reported in approximately 25% of the 
cases,45 there is a lack of data regarding ERCC1 and BRCA1 
expression levels between primary tumor and metastatic 
sites. Also, not much is known regarding the changes in 
the expression profile after the exposure to chemotherapeu-
tic agents in vivo. In any case, the results of this study indi-
cate that potentially ERCC1 and BRCA1 expression levels 
in the primary tumor at the time of diagnosis could be used 
for customization of the second-line treatment of patients 
with NSCLC.
The results of this study should be interpreted with 
caution. The study was conducted retrospectively in a 
relatively small cohort of patients. Therefore, these find-
ings should be confirmed in a larger independent cohort of 
patients preferable in the context of a randomized trial in 
which cisplatin-based chemotherapy was used only in one 
arm. Ideally, the hypothesis that gene expression of the pri-
mary tumor could predict the efficacy of second-line che-
motherapy could be tested with a rebiopsy of the metastatic 
tumor at the time of progression. This strategy could allow 
the comparison between the expression values before and 
after treatment exposure and their predictive significance 
and could provide important information for the mecha-
nisms of acquired resistance to the initial treatment.
In conclusion, although our findings should be inter-
preted cautiously according to the limitations described 
earlier, our results suggest that the assessment of BRCA1 
and ERCC1 mRNA expression levels can be used to select 
NSCLC patients in that they would have benefit from plat-
inum-based combinations in the second-line treatment. 
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Further studies in a larger cohort of patients and other 
molecular markers are warranted to confirm these results.
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